BidaskClub downgraded shares of Sanofi (NYSE:SNY) from a hold rating to a sell rating in a report published on Monday, July 24th.
SNY has been the subject of several other reports. HSBC Holdings plc downgraded Sanofi from a hold rating to a reduce rating in a research report on Friday, April 7th. J P Morgan Chase & Co restated a sell rating on shares of Sanofi in a research report on Thursday, March 30th. Zacks Investment Research downgraded Sanofi from a buy rating to a hold rating in a research report on Tuesday, April 25th. Argus began coverage on Sanofi in a research report on Thursday, April 6th. They set a buy rating and a $50.00 price objective for the company. Finally, Berenberg Bank downgraded Sanofi from a buy rating to a hold rating in a report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the stock. Sanofi has a consensus rating of Hold and an average target price of $63.75.
Shares of Sanofi (SNY) opened at 47.55 on Monday. The stock has a 50 day moving average price of $47.99 and a 200-day moving average price of $46.11. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The stock has a market capitalization of $119.42 billion, a price-to-earnings ratio of 11.23 and a beta of 0.88.
Sanofi (NYSE:SNY) last issued its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The firm’s quarterly revenue was down 2.3% compared to the same quarter last year. On average, equities research analysts predict that Sanofi will post $3.26 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “BidaskClub Lowers Sanofi (SNY) to Sell” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.com-unik.info/2017/08/12/sanofi-sny-lowered-to-sell-at-bidaskclub-updated-updated.html.
Several hedge funds have recently made changes to their positions in the stock. Pennsylvania Trust Co boosted its stake in shares of Sanofi by 0.4% in the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock valued at $402,000 after buying an additional 37 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in shares of Sanofi by 0.7% in the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock valued at $347,000 after buying an additional 47 shares in the last quarter. Weik Investment Services Inc. boosted its stake in shares of Sanofi by 0.9% in the first quarter. Weik Investment Services Inc. now owns 5,895 shares of the company’s stock valued at $267,000 after buying an additional 50 shares in the last quarter. Strategic Global Advisors LLC boosted its stake in shares of Sanofi by 0.6% in the second quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock valued at $414,000 after buying an additional 54 shares in the last quarter. Finally, Financial Advisors Network Inc. boosted its stake in shares of Sanofi by 1.0% in the first quarter. Financial Advisors Network Inc. now owns 8,282 shares of the company’s stock valued at $409,000 after buying an additional 84 shares in the last quarter. 9.96% of the stock is owned by institutional investors.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.